about
Fcγ and Complement Receptors and Complement Proteins in Neutrophil Activation in Rheumatoid Arthritis: Contribution to Pathogenesis and Progression and Modulation by Natural ProductsComplement regulation at the molecular level: The structure of decay-accelerating factorC1 esterase inhibitor reduces lower extremity ischemia/reperfusion injury and associated lung damage.A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial.Complement-targeted therapeuticsNew insights of an old defense system: structure, function, and clinical relevance of the complement system.Development of complement therapeutics for inhibition of immune-mediated red cell destructionManipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.Progress and Trends in Complement TherapeuticsIdentification of a complement receptor 1 peptide for inhibition of immune hemolysisComplement in immune and inflammatory disorders: therapeutic interventions.New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities.The innate immune system and transplantationAntibody-mediated xenograft injury: mechanisms and protective strategies.APT070 (mirococept), a membrane-localizing C3 convertase inhibitor, attenuates early human islet allograft damage in vitro and in vivo in a humanized mouse model.Protection of host cells by complement regulators.Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicityFurther studies of the down-regulation by Factor I of the C3b feedback cycle using endotoxin as a soluble activator and red cells as a source of CR1 on sera of different complotype.APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.Postexit surface engineering of retroviral/lentiviral vectors.Expanding horizons in complement drug discovery: challenges and emerging strategies.
P2860
Q26783178-633747D6-90F1-413D-B0C0-9692853DE353Q27643002-93C6E355-A166-4105-AD55-6BC9A8A74865Q31132259-ED6F0589-AEAE-4E97-BCFC-30217E2D6806Q33771461-BDCA4289-CBBC-499A-965D-D8BD7F4B5633Q34255011-18BC8C3D-10C8-4FED-8720-B8078513A98AQ34699496-80D8D547-811C-4E82-9174-FA0C61C2C62FQ36222203-B01CE1E8-5C6F-461C-AAC2-E710B02FCBE6Q36463266-8058F937-0954-4A08-9897-3A8C693C92A4Q36479278-BB25A580-5BEA-4023-9FAE-453B9026583EQ36719729-E9927ED7-827F-440F-93F0-500E381ED53DQ36756854-FB54D692-96DF-4DDB-9FFF-F9EDD82791B6Q37180522-B4E6EBA6-08A6-428D-A5AE-BC88DB6F8607Q37201483-BEEB8ACD-F116-47A9-B1D5-36F489792E01Q37450148-09FC7865-CE79-4523-9725-3829127E2F98Q38411332-AAEDAC9E-369A-492A-ADA3-CA1B44D3EDE4Q38991019-7343EDEE-2104-4657-9411-1EE157F6353EQ39735226-12521F65-AA61-46A5-AF67-59A9C72B6013Q40977039-11A00A86-809E-4C5F-8407-FBA11B68590FQ42121465-82AC3A23-9547-4EC2-9F6B-293D0BE28F46Q43095136-3FF34A3E-3FAB-40CB-B62A-6C92D200F82BQ44035393-7AB7A195-E0A0-4762-B03E-62DA43FB481DQ49439487-77B36102-5148-49E6-B07F-4CE73947FE9F
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Targeting anticomplement agents.
@ast
Targeting anticomplement agents.
@en
type
label
Targeting anticomplement agents.
@ast
Targeting anticomplement agents.
@en
prefLabel
Targeting anticomplement agents.
@ast
Targeting anticomplement agents.
@en
P356
P1476
Targeting anticomplement agents.
@en
P2093
P304
P356
10.1042/BST0301037
P577
2002-11-01T00:00:00Z